Crawford & Company® (NYSE: CRD-A and CRD-B), is pleased to announce its financial results for the third quarter ended ...
Delivered Q3 2025 revenue of $83 million Q3 2025 non-dermatologic revenue increased by 67% over Q3 2024 Q3 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) ...
Strong operating performance delivered double-digit growth on both the top and bottom lineRaising full year 2025 guidance and issuing full year 2026 guidanceAnnounces business combination with Husky ...
Net sales, Group total decreased to EUR 144.3 (146.6) million Net sales from continuing operations decreased to EUR 108.1 (113.7) million Comparable EBITA, Group total grew to EUR 9.6 (8.7) million, 6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback